| pubmed-article:2272537 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2272537 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2272537 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:2272537 | lifeskim:mentions | umls-concept:C0026473 | lld:lifeskim |
| pubmed-article:2272537 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2272537 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:2272537 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2272537 | pubmed:dateCreated | 1991-2-26 | lld:pubmed |
| pubmed-article:2272537 | pubmed:abstractText | Serum aldolase concentrations were determined in 78 patients with acute myelogenous leukaemia (AML). Mean serum aldolase concentration (+/- SD) at the time of diagnosis was 28.3 U/L (+19.4). 71.8% of AML patients had increased serum aldolase concentrations. The highest hyperaldolasaemia were observed in patients with acute myelomonocytic leukaemia and acute monoblastic leukaemia. The monocytic involvement in AML patients was significantly related to serum aldolasaemia. Human aldolase gene has been located on chromosome 16, whose structural aberrations are frequent in AML patients with monocytic involvement, explaining the link between serum hyperaldolasaemia and the monocytic involvement in AML patients. | lld:pubmed |
| pubmed-article:2272537 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2272537 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2272537 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2272537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2272537 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2272537 | pubmed:issn | 0017-6559 | lld:pubmed |
| pubmed-article:2272537 | pubmed:author | pubmed-author:ReesJ KJK | lld:pubmed |
| pubmed-article:2272537 | pubmed:author | pubmed-author:HassanH THT | lld:pubmed |
| pubmed-article:2272537 | pubmed:author | pubmed-author:RagabM HMH | lld:pubmed |
| pubmed-article:2272537 | pubmed:author | pubmed-author:ZyadaL ELE | lld:pubmed |
| pubmed-article:2272537 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2272537 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:2272537 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2272537 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2272537 | pubmed:pagination | 73-7 | lld:pubmed |
| pubmed-article:2272537 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:meshHeading | pubmed-meshheading:2272537-... | lld:pubmed |
| pubmed-article:2272537 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2272537 | pubmed:articleTitle | The effect of monocytic involvement of hyperaldolasaemia in patients with acute myelogenous leukaemia. | lld:pubmed |
| pubmed-article:2272537 | pubmed:affiliation | Department of Haematological Medicine, University of Cambridge Clinical School, United Kingdom. | lld:pubmed |
| pubmed-article:2272537 | pubmed:publicationType | Journal Article | lld:pubmed |
